2023
JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL. Neuro-Oncology 2023, 25: ii12-ii13. PMCID: PMC10489492, DOI: 10.1093/neuonc/noad137.034.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaBrain metastasesRadiation therapyLesion uptakeDiagnostic performancePredictive valueProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialInterpretation criteriaNegative predictive valueLow background uptakePositive predictive valueExcellent diagnostic performanceBM recurrencePost-MRIPrimary endpointSecondary endpointsRadiation necrosisReference lesionsUnnecessary surgeryHistopathological analysisInitial cohortEvaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. Journal Of Clinical Oncology 2023, 41: 2001-2001. DOI: 10.1200/jco.2023.41.16_suppl.2001.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaF-fluciclovine PETF-fluciclovine uptakeBrain metastasesF-fluciclovineRadiation therapyDiagnostic performanceHistopathological analysisSUV maxFirst prospective multicenter trialProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialProspective multicenter trialIndependent blinded readersFluciclovine uptakePost-MRIPrimary endpointSecondary endpointsMulticenter trialRadiation necrosisRecurrent tumorsFuture trials
2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2019
RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS
Kluger H, Forsyth P, Khushalani N, Eroglu Z, Sznol M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS. Neuro-Oncology 2019, 21: vi220-vi220. PMCID: PMC6847787, DOI: 10.1093/neuonc/noz175.919.Peer-Reviewed Original ResearchVEGF inhibitorsPrimary endpointPD-1/PD-L1Anti-PD-1 activityGrade 3 ALT elevationPre-specified primary endpointPhase 2 studyPhase 2 trialUnconfirmed PRALT elevationDiverticular perforationMetS patientsCerebral edemaPD-L1Wound dehiscencePembroToxicity profileEdemaFurther studiesPromising activityEndpointBRAFmtPembrolizumabMucositisULNFrequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors
Qian JM, Yu JB, Mahajan A, Goldberg SB, Kluger HM, Chiang VLS. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: 1113-1118. PMID: 31479702, DOI: 10.1016/j.ijrobp.2019.08.053.Peer-Reviewed Original ResearchConceptsBrain metastasesLocal therapyNeurologic safetyMelanoma patientsProspective phase 2 trialProgressive brain metastasesSerial brain imagingMelanoma brain metastasesPD-1 inhibitorsPhase 2 trialRapid disease progressionManagement of patientsNeurologic symptomsMultidisciplinary careTrial enrollmentCystic changesClinical trialsDisease progressionPatientsLesion sizeMetastasisMultidisciplinary teamTumor growthTherapyClinical decision
2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/s1470-2045(16)30053-5.Peer-Reviewed Original ResearchConceptsProgressive brain metastasesUntreated brain metastasesBrain metastasis responseYale Cancer CenterBrain metastasesPhase 2 trialCell lung cancerAdverse eventsMetastasis responseCancer CenterLung cancerMelanoma cohortGrade 3 colitisGrade 3 fatigueGrade 3 pneumonitisPD-1 axisAcute kidney injuryNeurological adverse eventsPD-1 inhibitorsAcceptable safety profilePD-L1 expressionSystemic immunotherapyKidney injuryPrimary endpointNSCLC cohortA contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report.
Colaco RJ, Yu JB, Bond JS, Bindra RS, Contessa JN, Knisely JPS, Chiang VL. A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. Journal Of Radiosurgery And SBRT 2016, 4: 43-52. PMID: 29296425, PMCID: PMC5658834.Peer-Reviewed Original ResearchWhole brain radiotherapyDistant intracranial recurrenceLocal recurrenceBrain metastasesRTOG 90Overall local recurrence ratePrevious whole-brain radiotherapyProspective phase 2 trialWhole-brain radiation therapyBrain radiation therapyLocal recurrence rateMonths overall survivalPhase 2 trialRisk regression analysisGuideline dosesBrain radiotherapyPrimary endpointIntracranial recurrenceOverall survivalFine-GrayPrescription dosesRecurrence rateRetrospective outcomesMedical recordsLesion volume